http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022101463-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68f0fa6a3ba9a5efb89ecdae98e9790b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d0f93a136a676c6b153808b7c56e599 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24122 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2021-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcd3b2d4e3523e3b1aaaeb3cdf23b5b7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f191026971f06602796bec7259ad22f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efe42049ad48d8ef04419dab35b8d5c0 |
| publicationDate | 2022-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022101463-A1 |
| titleOfInvention | Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death |
| abstract | Apoptosis is the main mechanism by which Mosquito-borne Zika virus infection causes cell death. Here, the inventors aimed to determine whether the last C-terminal residues M31/41 of ZIKV M ectodomain can trigger apoptotic cell death. Apoptosis was detected in human hepatoma Huh7 cells expressing of a recombinant GFP which includes ZIKV M oligopeptide at its C -terminus. The triggering of apoptosis requires translocation of ZIKV M oligopeptide in the secretory pathway and involves caspase-3 activation. The inventors then assessed whether ZIKV M oligopeptide has ability to confer death-promoting activity to a secreted tumor-associate antigen such as megakaryocyte-potentiating factor (MPF) which is a cleaved product of human mesothelin. Expression of MPF with ZIKV M oligopeptide linked to its C -terminus resulted in induction of apoptosis in human pulmonary adenocarcinoma A549 cells as well as human hepatoma Huh 7 cells. Given that ZIKV has been proposed as an oncolytic virus for cancer therapy, the ability of ZIKV sequence RVENWIFRNPG (called ZAMP for Zika Apoptosis M Peptide) (SEQ ID NO:l) to confer pro-apoptotic activity to a tumor-associated antigen such as MPF opens up new attractive perspectives for ZAMP as innovative anti-cancer agent. |
| priorityDate | 2020-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1089.